1383
PŘEHLEDOVÉ479422001004388130181216258306358404446
ČLÁNKY525622001003973122176223272
Pokroky361633001004079114139178212251
v3883330010035
diagnostice39343300100375287125163202231259275305339
a4289330010034
léčbě43393300100155082120156
systémového45113300100286595122157217256292327364403
lupus49303300100155391129157
erytematodes51043300100345897126161221255282320359394424
|5584220010018
383564222001003476111
/35988040010732
Vnitř3675804001074592111139166
Lék.3860804001074184122140
2025;71(6):377-3834020804001074487128172185226267286327350364409449493516556600643
/47088040010731
VNITŘNÍ48058040010746106127172220280301
LÉKAŘSTVÍ5127804001074185130188236280325378400
www.casopisvnitrnilekarstvi.cz42580400107651332012142542953293774274464795215705896176436927117307748128548809159449871007102310631101
10.425550085367085
Italiani52355008315377085100132170185
P,7215500833540
Manca7745500835487125157190
M,9775500835468
Angelotti10585500834179118153169207229253268
F,13395500833339
et13915500833356
al.1460550083324760
IL-1153355008315476292
family16385500831952110125140172
cytokines1823550083316590127157174211246273
and21095500833270109
soluble2231550083266580118157173208
receptors2452550083215587121160182219241268
in27335500831553
systemic27995500832658854256500832255113128160
lupus601650083155291129156
erythematosus.772650083345589114152187245278299336363400426440
Arthritis1227650083416387125147162185200226
Res1468650083367198
Ther.15816500833272107128138
2018;20:27.17356500833468100131143178212225260293299
11.425750085366678
Suh5207500833270108
CH,644750083408497
Kim7577500833552109
SS,882750083336578
Hong9767500834483121160
SJ,1152750083335769
et12377500833457
al.1310750083324760
Novel13867500834583115149165
diagnostic1567750083385385124162201227251266298
biomarker1881750083395492150183204235269290
of21877500833757
systemic2260750083265886109142200215247
lupus2524750083145291129156
erythematosus26967500833455891141521874258500835993116154182221249
–69685008336
antichaperonin754850083337295111145184218259296318357397413453
containing12298500833270111133168184223239279319
T-complex1570850083345388127187228245282314
peptide19078500833977117141157197234
1216385008335
antibody.2220850083337395112152193234267278
J252085008325
Rheumatol.25678500833777113153213247269308325339
2025;52(Suppl4259500833468101136147182215232264301341380396
1):99-100.83695008335496196131155186217253266
12.4251050085366884
Fanouriakis52210500833262100138176197213245275291317
A,85210500834155
Kostopoulou9201050083357399122159199238276291329367
M,130010500835468
Andersen138110500834179118153174201236274
J,166810500832436
et171710500833456
al.17861050083324860
EULAR185910500833376108151187
recommendations20591050083215587124182240275313352384406421459498524
for25961050083185678
the26871050083215994
management27941050083589042511500833870109144202237275296
of73411500833757
systemic8041150083265885108142200215247
lupus10641150083155291130156
erythematosus:12331150083345589114152187245277299336362400426438
2023168411500833569101136
update.183311500833776116148170204216
Ann206211500834179117
Rheum219211500833574109146204
Dis.24091150083456187101
2024;83:15-29.252311500833468101132144180213225255285307337372383
13.4251250085366883
Kidney5291250083355190128163195
Disease:7441250083456187122154180215228
Improving99212500831573112133171203218256295
Global13081250083435997137170185
Outcomes151412500834785108138175234269295
(KDIGO)183012500831853100116161208226
Lupus207712500833168107145172
Nephritis226912500834580119157178194217232258
Work254712500835894116146
Group.271412500834365102140179192
KDIGO4251350083358298142190
202463313500833468101133
Clinical7851350083405570108123155188203
Practice10061350083365689121145161193226
Guideline12511350083448297136171186201239274
for15441350083185677
the16401350083215994
Management175313500835487125157196231289324362384
of215513500833757
Lupus223013500833269108146172
Nephritis.242113500834479119157178194216232258271
Kidney27111350083355190128163195
Int.425145008315537488
2024;105(1S):S1-S69.52814500833468101133145175206240258290318337349383413432463499533544
14.4251550085366984
Horák52615500834482104137167
P.70915500833541
Principy7661550083355671109141156195227
léčby10091550083155082121152
SLE11781550083326396
dle12901550083395489
aktualizovaných13951550083326286124157172187216253285318356387418456
doporučení186815500833876115154176214246280318333
EULAR221715500833376108151187
2023242015500833468101136
–2572155008335
komentář.262315500833067126161199220253274283
Čes42516500834074101
Revmatol.54116500833570102161193215252268281
2024;32(3):107-115.83716500833468101133145180213230264281293322354386405436464494506
15.4251750085366883
www.sukl.cz.523175008351104157168195233263279292324355369
Available90717500834172104120135167206222257
from:11791750083194178136148
https://www.sukl.cz13431750083375983123149162189209260313367378405442472489502534564
16.4251850085366984
Wallace52218500835788103118150182215
DJ,7501850083456778
Stohl8411850083325390128143
W,99718500835766
Furie10761850083326889104138
RA,12271850083357892
et133118500833456
al.14001850083314659
A1472185008340
phase152518500833877108135169
II,17071850083153042
randomized,17621850083205391129167225240268302341354
double-blind,212818500833876114152168202225265281295333371384
placebo-controlled,25241850083395586118152190229252285322360425195008322438096111146186198
dose-ranging63819500833876103138161183216254293308346385
study10371950083275088127159
of121019500833757
belimumab12811950083397490105162200258290330
in162519500831552
patients16921950083397293109143181203231
with19371950083516689127
active20781950083326488104136170
systemic22631950083265885109142200215247
lupus25251950083155291129156
erythematosus.2695195008334558911415218742520500835790111148175212239252
Arthritis6932050083406286125146161184199225
Care9342050083397293128
Res.10772050083357097111
2009;61:1168-1178.120320500833468104139152188218227257284315351374404432462495508
17.4252150085366876
Furie5182150083326990105140
R,67421500833549
Petri7392150083366991113128
M,88321500835568
Zamani96721500833871129161199214
O,119721500834758
et127121500833456
al.13432150083324860
A1419215008341
phase147621500833977110136171
III,1663215008315304558
randomized,17372150083215492131169227242272306345358
placebo-controlled21112150083385487119152192231254288324363384406443459474509548
study26752150083275088127159
of285021500833756
belimumab,4252250083387388103160197254285324335
a773225008331
monoclonal81722500835694132169201216254292323338
antibody11672250083326990105144182221252
that14312250083225991112
inhibits15552250083155290104143158180207
B1774225008335
lymphocyte182122500831546104142180218250283307340
stimulator,21742250083254863120157172203224261282291
in247822500831451
patients25422250083387092106140178199226
with27802250083506687125
systemic4252350083265986109143200216248
lupus6882350083155291130156
erythematosus.8592350083345589114152187245278299336363400427440
Arthritis13152350083406286125146161184199225
Rheum.155623500833573108146204217
2011;63:3918-3930.178823500833569100128136172206217252286318349371404437470504517
18.4252450085366985
Navarra52524500834577109142163184217
SV,7572450083337079
Guzman85024500834482112170202240
RM,110524500833691104
Gallacher12242450083447792107139171209244266
AE,15042450083417588
et160724500833356
al.16782450083314760
Efficacy1753245008332506886118151183216
and198424500833270109
safety21082450083265978112135168
of229124500833757
belimumab23632450083387489104162200258290329
in270724500831552
patients277424500833972941094252550083347294121
with5622550083506688127
active7042550083326488103136170
systemic8902550083265885108142200215247
lupus11532550083155291129156
erythematosus:13242550083345589114152187245278299336363400427439
a1779255008331
randomised,18262550083205391130169227242268303343355
placebo-controlled,21972550083385487119152192230254287324363384406443459474509548561
phase27742550083387710942526500832661
3501265008335
trial.551265008322435991106119
Lancet.68526500833265103135169191205
2011;377:721-731.90526500833468100128136171203237247281315347365397431462471
19.4252750085366982
Stohl5262750083325491129144
W,68927500835867
Schwarting77527500833365103153186207232247285324
A,111827500834155
Okada119227500834778111150183
M,139327500835568
et148027500833456
al.15552750083324760
Efficacy1634275008333506886118151183217
and186927500833270109
safety19972750083265978113135169
of218527500833756
subcutaneous226027500832663102135173195228266301340378404
belimumab2683275008339749010516320042528500835790129
in57028500831553
systemic6392850083265986109142200216247
lupus9032850083155291129156
erythematosus:10752850083345589114152187245277299336363400426439
a1530285008332
fifty-two–week1578285008317345378112134156209247285336371406436
randomized,20312850083205391130169227242271305345357
double-blind240528500833876114153169204227267283298336375
placebo-controlled2796285008339558742529500833165104143166200237275297318356371387421461
study.9012950083265087127158168
Arthritis10852950083416287125146162184199225
Rheumatol.132629500833574109146204236258295311324
2017;69:1016-1027.166529500833469100130140175209222252284315346370401432465498504
20.4253050085367287
Zhang52630500833876108146185
F,72530500833238
Bae77730500833568103
SC,8943050083337386
Bass9943050083356895122
D,113030500834556
et120030500833456
al.12703050083324760
A1344305008341
pivotal13993050083385486124146179194
phase160730500833977109136171
III,1792305008315304558
randomised,18643050083205392131169227242268303343355
placebo-controlled22333050083395587119153192231254288325363385406444460475509549
study2796305008326498742531500833870
of51031500833756
belimumab5813150083387490105162200258290329
in92531500831552
patients9923150083397293109143182203231
with12373150083516789127
systemic13793150083265886109142200215247
lupus16413150083155292130156
erythematosus18123150083345589114152187245277299336363400426
located22533150083155385118140174213
in248131500831452
China,25483150083407893131163176
Japan27393150083245695128166
and42532500833270109
South54932500833371109132170
Korea.7343250083357394128160173
Ann92332500834179117
Rheum105532500833574109147204
Dis.12753250083456187100
2018;77:355-363.139132500833468100131143176210220256289321343375410444456
21.4253350085367082
Furie5203350083326990105140
R,67333500833650
Rovin73633500833574106121159
BH,9083350083368193
Houssiau101533500834482120147173188220258
F,128633500833238
et133733500833457
al.14073350083324760
Two-year,148033500833380117141173207239260270
randomized,17633350083215492131169227242271305345358
controlled213433500833168106128149187203218253292
trial2439335008322435991106
of255933500833756
Belimumab2628335008336718610115919725542534500833271
in51134500831553
lupus5793450083155392130156
nephritis.75034500833873112151172187210225251265
N1030345008345
Engl109034500833371110125
J1230345008324
Med.127034500835489129142
2020;383:1117-28.142734500833469101136148183218252263293321348378396427461474
22.4253550085367288
Atisha-Fregoso5343550083416277104141174196230250284324362388427
Y,98135500833543
Malkiel104535500835487102132148183199
S,126435500833245
Harris13293550083447798120135161
KM,151135500833491105
et163635500833456
al.17123550083324760
Phase179335500833572104131166
II197935500831530
Randomized202935500833669107146184242257286320360
Trial2409355008333506697113
of254235500833757
Rituximab26193550083355173111142158216248287
Plus4253650083355087114
Cyclophosphamide5583650083406899114152192231269296335373405463478517552
Followed11293650083337086101139190225264
by141236500833970
Belimumab15013650083367186101159197255287326
for18463650083195678
the19433650083226095
Treatment20573650083335084116138196231269290
of236736500833756
Lupus244236500833269108146172
Nephritis.263436500834479118157178194216231258271
Arthritis4253750083416287125146162184200226
Rheumatol66537500833573108146204236258295311
Hoboken99037500834482122161191225263
NJ.12673750083457083
https://doi.org/10.1002/13643750083375983122149162188209245283298311349371409435468500512543574611643670
art.2048375008332537791
41466.21533750083346495131167180
Epub234737500833372110149
ahead251037500833270105137176
of270037500833756
print27703750083396076114135
4425385008334
August47438500834178117155181205
2020.69438500833468101135148
23.4253950085367287
Furie5253950083326990105140
R,67839500833549
Khamashta74039500833574106164196223261282315
M,106839500835468
Merrill114939500835489110132147163178
JT,13403950083245867
et142039500833456
al.14893950083324760
Anifrolumab,15623950083417994113135172188226283316355367
an194239500833270
Anti-Interferon-α202539500834179100115137154192213247268290324345382421443483
Receptor252139500833570102136175197234256
Monoclonal27903950083549242540500833775108123161199231246
Antibody,68440500834179100115154193232264273
in97040500831452
moderate-to-severe103540500835795134169190223244278301323360383409444476510531565
systemic16134050083265885108141199214246
lupus18714050083155291129155
erythematosus:20394050083345589113151186243276297334360397423436
Anifrolumab24874050083417994113135172188225282315353
in285340500831552
moderate-to-severe42541500835796135170191224246280303325362386413448480514535569
SLE.10104150083326397110
Arthritis11354150083416287125146162184200226
Rheumatol.137641500833574109146204237258295311324
2017;69:376-86.171641500833468100129139174208221257289321344380415429
24.4254250085367186
Furie5294250083326990105140
RA,6874250083367993
Morand79842500835593114147185225
EF,10414250083326571
Bruce11304250083355795127161
IN,13094250083156073
et140042500833456
al.14754250083314760
Type155342500833260100136
I1707425008315
interferon17404250083155274108129150185206243282
inhibitor20404250083155391106145160183220241
anifrolumab23004250083316984104126163179216274307346
in266442500831553
active27354250083326488103136170
systemic4254350083265986109143200216248
lupus6914350083155291129156
erythematosus8654350083345589114152187245277299336363400426
(TULIP-1):13104350083185499131147182203234249260
a1589435008331
randomised,16394350083205391130169227242268303343355
controlled,201243500833269107129150187203218253293305
phase233643500833877109136171
32525435008334
trial.2577435008322435991106119
Lancet271443500833265103135169191
Rheumatol.42544500833574109146204237258295311324
2019;1:e208-19.76544500833468100130143173181216250284320342373403414
25.4254550085367287
Morand52545500835492114147184223
EF,7614550083336571
Furie8454550083326889104139
R,99745500833549
Tanaka10594550083326098130160193
Y,126545500833543
et132145500833456
al.13904550083314760
Trial1462455008333506597112
of158745500833757
Anifrolumab16564550083417994113135172188225283315354
in202345500831452
active20884550083326488103135169
systemic22704550083265885108142199214246
lupus25294550083155291129155
erythematosus.2697455008334558911315118642546500835790111148175212239252
N693465008344
Engl75346500833270109124
J893465008324
Med.93246500835490129142
2020;382:211-21.109046500833468101135148183217251263298330357376407438448
26.4254750085367187
Jayne5314750083245687126161
D,71147500834556
Rovin78547500833674106122160
B,96347500833648
Mysler103047500835586113128163184
F,123347500833238
et129047500833456
al.13654750083324760
Phase144447500833572105131166
II162947500831530
randomised16784750083205391130168227242268303342
trial2039475008322435991106
of216447500833756
type22394750083225595131
I2389475008314
interferon24224750083155374108129151185206244282
inhibitor272347500831452901051441604254850083225980
anifrolumab5204850083327085104126164180217275307346
in88148500831553
patients9494850083387193108143181203230
with11944850083516689127
active13364850083326488103136170
lupus15214850083155292130156
nephritis.169248500833873112150171187209225251264
Ann197148500834179117
Rheum210348500833674109147205
Dis.23234850083456087100
2022;81:496-506.243848500833468101136148183215224258291327350384418454467
27.4254950085367180
Merrill52449500835490111133148163178
JT,7214950083245968
Neuwelt80749500834580118169204219242
CM,106749500834095109
Wallace119549500835788104119151183217
DJ143149500834567
et151749500833456
al.15924950083324760
Efficacy1671495008332506886118151183216
and190649500833270109
safety20344950083265978112135168
of222149500833757
rituximab2297495008320365896128143201233272
in258849500831553
moderately-2659495008358961361711922254255050083225571103125
-to5675050083214380
-severely6655050083204782115149170204220252
active9345050083326488103136170
systemic11215050083265986109143201216248
lupus13865050083155292130156
erythematosus:15595050083345690114153188246278300337363401427439
the20165050083215994
randomized,21285050083205391130169227242271305345357
double250350500833876114153169204
-blind,2724505008321617792130169182
phase42551500833977109136171
II/III61551500831530557187102
systemic7365150083265885108142200215247
lupus10025150083155291130156
erythematosus11775150083345589114152187245277299336363400426
evaluation16225150083346699114152184206221259298
of193851500833857
rituximab2014515008320365896128143201233273
trial.2305515008322435991106119
Arthritis24435150083416287125146162184200226
Rheum.268751500833674109147205218
201042552500833468100131
Jan;62(1):222-33.5725250083245694106142175192224239250286320355376408441453
28.4255350085367287
Rovin52553500833573105120158
BH,6965350083358092
Furie8015350083326889105139
R,95353500833549
Latinis10155350083316486101138153179
K,120753500833549
et126953500833456
al.13375350083324760
Efficacy1410535008332506885117150182215
and163853500833169108
safety17595350083265977111134167
of193953500833756
rituximab2008535008320365896127142199231270
in229153500831552
patients23565350083397193108142180201229
with25985350083506588126
active27365350083326488103135169
proliferative4255450083386096112127146180200233254269301335
lupus7735450083145190128154
nephritis:93954500833772111149170185207222248260
the12115450083225994
Lupus131754500833268107145170
Nephritis150054500834479118156176192214229254
Assessment17675450083416894129155181238273311332
with21115450083506688125
Rituximab22495450083355072110141156213245284
study.25455450083264986125156166
Arthritis272454500834061851231441594255550083213762
Rheum.50055500833573108145202215
20127285550083346899129
Apr;64(4):1215-26.86955500834180101114150186205237255266296325356386408438472485
doi:13665550083387691103
10.1002/art.34359.14815550083346578108139175208234264285309322357392424457489500
Epub199355500833371109148
201221535550083346899129
Jan22955550083245593
9.240155500833444
PMID:245855500833588103149161
22231479.263255500833468103137168198230263274
29.4255650085367285
Gomez52756500834482141176205
Mendez74856500835590128167202231
LM,99556500833287101
Cascino11125650083397299131146184222
MD,1350565008355101112
Garg14785650083437697135
J,162956500832436
et168156500833456
al.17535650083324760
Peripheral18295650083356990106145183218240273288
blood21335650083385493131171
B2320565008335
cell2371565008331658096
depletion248256500833973113129163186201239277
after27755650083325176110131
rituximab425575008320365895126141198229268
and70557500833269107
complete82557500833167124163178213234268
response11055750083205480118157194220255
in137257500831452
lupus14365750083155290128153
nephritis.160257500833771110148168184206220246259
Clin18745750083395468106
J1992575008324
Am202857500834198
Soc213857500833270102
Nephrol.225257500834579118156176213228241
2018;13:1502-9.25055750083346799129141170200211240270303335355390400
30.4255850085367287
Kalunian5305850083356884121159174206244
KC,7925850083347486
Merrill89658500835489110132148163178
JT,10915850083245968
Maciuca117658500835487119134171204236
R,143058500833549
et149658500833456
al.15695850083324861
A1647585008341
phase170558500833877109136171
II189358500831530
study19405850083264987126158
of211658500833756
the21895850083226095
efficacy2301585008334537088120153185219
and253758500833270109
safety26635850083265978113135169
of284958500833756
rontalizumab4255950083205794115147162176205242299330369
(rhuMAb8065950083183775111165206245
interferon-α)10635950083145172105126147180201237275297335353
in142859500831552
patients14925950083387091106140177198225
with17295950083506587124
systemic18655950083265884107139196211242
lupus21195950083155190127153
erythematosus22845950083335487111148183239271292328354390416
(ROSE).271259500831853100132164183193
Ann42560500834179117
Rheum55760500833674109147205
Dis.7776050083456187101
2016;75:196-202.89360500833468100131143176209220250280315339370404437449
31.4256150085366981
Khamashta51961500833574106164196223260282314
M,84661500835468
Merrill92761500835489110132147162177
JT,11176150083245967
Werth119761500835891112136174
VP,13846150083367277
et147461500833456
al.15436150083314759
Sifalimumab,16156150083334766100115130187225283315354366
an199461500833169
anti-interferon-α20766150083327091106129145182204237258280314335372411433472
monoclonal256161500835896134172205220258296329344
antibody,4256250083327091106145184223255265
in70362500831452
moderate76862500835795135169191223245279
to106062500832158
severe11316250083266193127148182
systemic13266250083265885108142200215246
lupus15856250083155291130156
erythematosus:17546250083335588113151186244276298334361398424437
a2204625008331
randomised,22486250083215492130168227242268302342354
double-blind,2615625008338761141531692042272674256350083153068107119
placebo-controlled5606350083385486119152192230254287324363384406443459474509548
study.11246350083264987126158168
Ann130763500834179117
Rheum144063500833573108146204
Dis.16596350083466187101
2016;75:1909-1916.177563500833468100131144177209220250280316351375406436468499512
32.4256450085367086
Furie5246450083326889104139
R,67664500833548
Dooley73764500834583122138172203
MA,95364500835496110
Wofsy107564500835793113140172
D,126064500834556
et132864500833456
al.13976450083314659
A1469645008341
phase152264500833977109135170
III17046450083153045
randomised,17626450083205391129167225240266300340352
double-blind,212764500833876113152168202225265281295333372384
placebo-controlled25246450083385486118151190228251285321359425655008322438096111146186
study6276550083265088127159
to80265500832259
evaluate8776550083346699115152185206240
the11346550083215994
efficacy1245655008334527088120153185219
and148065500833270109
safety16066550083265978112135168
of179165500833757
abatacept186465500833271104126159191225264286
or216665500833859
placebo22426550083395487119152192231
on248965500833776
standard25816550083275082121160192213251
of284965500833756
care4256650083316485119
in56066500831452
patients6276650083397294109144182203231
with8746650083506688126
active10166650083316488103136170
class12016650083314779105132
III13486650083153046
or140966500833759
IV148366500831552
lupus15506650083155291130156
nephritis.172166500833873112150172187210225251265
Ann200166500834179117
Rheum213366500833674109147205
Dis.23536650083456187101
2018;77:176-177.246966500833468100131143176211221250280312335366395430436
33.4256750085367186
Furie5256750083326990105140
RA,6796750083357892
Leon78567500833266104143
G,94267500834357
Thomas101367500833271110168200227
M,125467500835468
et133567500833457
al.14056750083324860
A1479675008341
phase153467500833977109136171
2,171967500833446
randomised,17796750083215492131169227242269304343356
placebo-controlled21496750083385486119152191230254287324363384406443459474509548
clinical2711675008331476199114146179195
trial425685008322435991106
of54468500833756
blisibimod,613685008339557096111150165223261301313
an93968500833270
inhibitor10226850083155391106145160183220241
of127668500833757
B1346685008335
cell1394685008331658095
activating15026850083326488104136169191206244283
factor,17986850083185284108145166176
in198768500831553
patients20536850083387193108143181202230
with22966850083506688127
moderate-to-severe2436685008357951351701912242452793023253613854124474256950083316585118
systemic5556950083265884107140196211242
lupus8096950083155190127152
erythematosus,9746950083335487111148182239270292328354390415428
the14146950083215993
PEARL-SC151969500833566108143174189219259
study.17906950083264885123155164
Ann196669500834178115
Rheum209369500833572106143200
Dis.2305695008345608598
2015;74:1667-1675.24156950083346798127138170199211240270305337355385415447479491
34.3047550085367388
Merrill31485500835489110132147162177
JT,3338550083245867
Shanahan34185500833270102140172210242279
WR,37105500835794107
Scheinberg38305500833365102137152190229264285323
M,41665500835467
et42465500833456
al.4315550083324760
Phase43875500833573105131166
III4566550083142945
trial462355008322435990106
results4742550083205481118133155182
with4937550083516688126
blisibimod,507655008339546995110149164221259299311
a540055008332
selective544555008326603047650083155082106122154189
inhibitor3254650083145290105144160182219241
of35136500833757
B-cell3588650083355891125141156
activating3762650083326488103136169191206244283
factor,4063650083185284108145166176
in42576500831553
subjects43286500832663102118153185209237
with4583650083516689127
systemic4728650083265986109143200216248
lupus4994650083145291129156
erythematosus51686500833455891141521872452772993363047750083266390
(SLE):3153750083185081114134146
results3315750083215581119134156184
from3515750083184178136
a366775008332
randomised,3715750083205391130169227242268303343355
double-blind,40867500833877115154170205228268284299336376388
placebo-controlled4490750083395587119153192231254288325363385406443459474509549
trial.505575008321435890106119
Ann51907500834179117
Rheum53237500833574108146204
Dis.3047850083456187101
2018;77:883-889.31638500833468100131143176211221255291325347383418452463
35.3047950085367186
Isenberg3153950083154176114153189210248
DA,34219500834685100
Petri3541950083356891112128
M,36899500835568
Kalunian3777950083356984122160175207245
K,40429500833550
et41129500833456
al.4188950083324860
Efficacy426995008332506886118151183216
and45069500833270109
safety4635950083265978113135169
of48249500833756
subcutaneous49019500832663102135173195228266301340378404
tabalumab5325950083225594127142180304710500835891130
in319810500831553
patients32721050083397395110145184206234
with35271050083516789128
systemic36761050083265987110144203218251
lupus39481050083155392131158
erythematosus:41261050083355691116155190249281303341368406432445
results45921050083215582120136158187
from47991050083194179138
ILLUMINATE-1,49581050083154779123178194239281310345367398407
a5386105008332
52week,543910500833468304711500835185121151166
phase323311500833977110136171
III,3425115008315304558
multicentre,350311500835895111133149181214252274296330342
randomised,38651150083215492131169228243269304344356
double-blind,424211500833876114154169204228268284299337376388
placebo-controlled46511150083385487119153192231254288325363385407444460475510549
study.52211150083264987126158168
Ann541011500834179117
Rheum304712500833574109146204
Dis.32671250083456087100
2016;75:323-331.338312500833468100131143176209220255287322344376409440450
36.30471350085367187
Merrill314613500835488109130146160175
JT,33331350083245867
van341213500833164101
Vollenhoven35261350083357086100135172209247279312350
RF,38881350083356873
Buyon397413500833572103140178
JP,41651350083235963
et424013500833456
al.43081350083324759
Efficacy4379135008333506885117149181214
and460513500833269107
safety47251350083255877110132165
of490313500833755
subcutaneous497113500832662101133170192224262296334372397
tabalumab,53811350083215392124304714500831552110143182194
a3255145008331
monoclonal330014500835896134173205221259297330345
antibody36591450083327091106146184224256
to392914500832158
B-cell40011450083365892126141156
activating41711450083326488104136169191206244283
factor,44681450083185284108145167176
in465814500831553
patients47251450083387193108143181203230
with49691450083516689127
systemic51101450083265885109142200215247
lupus53711450083155392130156
erythematosus:30471550083345589114152186244276298335361398424437
results34971550083205481118133155183
from36931550083184077135
ILLUMINATE-2,38411550083154678121175190235276305339361391404
a4258155008331
52-week,43021550083346787139173208239253
phase456815500833877109135170
III,4751155008315304558
multicentre,482115500835895110133148180213251272294328339
randomised,51731550083215492130168226241267302342354
double-blind,304716500833876114154169204227267283298336375388
placebo-controlled34501650083395587119153192231254288325363385406443459474509549
study.40141650083264987126158168
Ann419816500834179117
Rheum433016500833674109147204
Dis.45501650083456187100
2016;75:332-340.466616500833468100131143176209220255288320341373409444457
37.30471750085367079
Isenberg31441750083154176114153189210248
D,340917500834657
Gordon348317500834483104142180219
C,371917500834053
Licu37901750083314678116
D,392417500834556
et399717500833456
al.40711750083324760
Efficacy4148175008333516986119151184217
and438217500833270109
safety45091750083265978112135168
of469517500833756
atacicept47691750083325386118133165199238260
for50471750083185677
prevention51421750083386094126161199220236274312
of547117500833857
flares3047185008317346687121148
in321018500831553
patients32781850083397293109143181203231
with35241850083506688127
moderate-to-severe366618500835795135170191224246280303325362386412447480514535569
systemic42501850083275986109143201216248
lupus45131850083155392130156
erythematosus46841850083345690114153188246278300337363401427
(SLE):51261850083195081115134146
52-week52881850083346787139173209239
data30471950083387092125
(APRIL-SLE31871950083196096131147178193225256289
randomised34911950083215492131169228243269304343
trial).3850195008321435890106125136
Ann400119500834180117
Rheum413419500833574109146204
Dis.43531950083466187101
2015;74:2006-2015.446919500833469100130141174204217252286322358381412446478508520
38.30472050085367288
Wu315520500835794
D,326820500834656
Li334420500833146
J,340920500832537
Xu346520500833874
D,355820500834556
et363320500833456
al.37082050083324860
Telitacicept3787205008333647994117150182197229263302324
in413020500831552
patients42012050083397294109144182203231
with44512050083516689127
active45972050083326488103136170
systemic47862050083265986109143201216248
lupus50532050083155291130156
erythematosus:5228205008334558911415218724527830472150083225987125151164
results32322150083215683121137160188
of344121500833857
a3519215008332
phase357221500834079112139174
23767215008335
b,381521500833951
randomised,38872150083215593133172231247273309349362
double-blind,427021500833978116156172208232272289304342382395
placebo-controlled46862150083395688121156195235259293331370392414452468483519559
trial.5266215008322446092108121
Ann540821500834281119
Rheum304722500833574109146204
Dis.32672250083456087100
2024;83:475-487.338322500833468101132144180214225259291324346383419452458
39.30472350085367185
Furie31472350083326990105140
R,330223500833650
Aroca336723500834162100132165
G,354823500834357
Alvarez36202350083415689122143177207
A,384223500834155
et391223500833457
al.39842350083324760
A4059235008341
phase411623500833877109136171
II430223500831530
randomized,43472350083215492131169227242272306345358
double-blind,472023500833876115154170204228268284298336375388
placebo-controlled512323500833955871191531922312542883253633853047245008321587489124163
study32232450083275088127159
to339524500832259
evaluate34672450083346699114152184206240
the37202450083216095
efficacy3828245008334527088120153185219
and406024500833270109
safety41822450083265978112135168
of436424500833756
obinutuzumab44332450083387793131168191229258296354387426
or487224500833759
placebo49442450083395587119153192231
in518824500831553
combination52542450083316812616518121925130472550083223775113
with31752550083506688127
mycophenolate331625500835788120157196235270308346362394416450
mofetil378025500835796115150172187202
in399725500831452
patients40642550083397193109143181203231
with43092550083516689127
active44502550083326488104136171
class46352550083314779105132
III47812550083153046
or484125500833759
IV491425500831552
lupus49802550083155392130156
nephritis515125500833772112150171187209225251
[abstract].5416255008319498830472650083264971104136160177189
Arthritis32522650083416287125146161184199225
Rheumatol.349326500833573108146204236258295311324
2019;71(Suppl383226500833468100130143176209224255293332371387
10).4235265008334658495
40.30472750085367387
Mysler314727500835485112126161182
EF,33412750083336470
Spindler34242750083327085123161176211231
AJ,36682750083416779
Guzman375927500834481110168200237
R,400927500833548
et407027500833456
al.41382750083324759
Efficacy4210275008332496785116149181214
and443627500833269108
safety45562750083265977111133166
of473527500833756
ocrelizumab48032750083376990124139154182220277309348
in516327500831552
active52282750083316387102134167
proliferative540827500833859963047285008315304984105138159175207242
lupus33032850083145291129156
nephritis:347228500833873112151172187210225251264
results37502850083205481118134156184
from39482850083184078136
a4098285008332
randomized,41432850083215492131169228243272306345358
double-blind,451528500833876114154170204227267283298336375388
phase491728500833977109136171
III51022850083153045
study.51612850083264987126158168
Arthritis5343285008341628712514616230472950083223763
Rheum.312529500833674109147205218
2013;65:2368-2379.335829500833469100130142177211222257292327362385416450482516527
41.30473050085377184
van315430500833267106
Vollenhoven32833050083367491107144184223263297333372
RF,36783050083367178
Hahn377830500834579119159
BH,39593050083368397
Tsokos40793050083335696128167195
GC,429730500834487101
et442030500833559
al.45013050083334963
Efficacy4587305008333527089122157190225
and483530500833272113
safety49703050083276282118142177
of517030500833758
ustekinumab,52513050083386590125157175214253304731500835891131144
an321331500833271
IL-123306315008314476395125
and345331500833271111
IL-233586315008315486395131
inhibitor,37393150083155392108148165188226248259
in402031500831453
patients40953150083397395112147186208237
with43543150083516790129
active45053150083326590106140175
systemic47023150083266088112146205221254
lupus49783150083155393132159
erythematosus:5159315008334569111715619225128430734530473250083266491104
results31673250083215583121137160188
of337132500833757
a3444325008332
multicentre,349132500835896112135151184218257279301336349
double-blind,385532500833977116156173208232273289305344383397
phase426732500833978111139174
2,445732500833447
randomised,45203250083215493133172231246273309349363
controlled489832500833169108130153191207223258299
study.52123250083265089129161172
Lancet.54003250083316510430473350083316689103
2018;392:1330-1339.316633500833569102134146182216250263294324358393418449480513547559
42.30473450085367086
Furie31463450083326990105140
RA,32993450083367893
Bruce34053450083355695127160
IN,35783450083156073
Dörner366434500834684106144179201
T,387834500833241
et393234500833456
al.40013450083324760
Phase407434500833673105132167
2,425434500833446
randomized,43133450083215492131169228243272306345358
placebo-controlled46843450083395587119153192231254288325363385406443459474509549
trial5246345008321435890106
of536534500833756
dapirolizumab54343450083387130473550083395475113128143173211269301340
pegol340035500833975114152168
in358135500831553
patients36473550083397294109144182203231
with38913550083516689127
moderate-to-severe403135500835796135170192225246280303326362386413448480514536570
active46143550083326488103136170
systemic47973550083265986109143201216248
lupus50583550083155292130156
erythematosus.5227355008334558911415218724527830473650083225985123149162
Rheumatology.322536500833573108146204236258295311349389421431
2021;60:5397-5407.367136500833468101133141177212225260294327360378412447483516522
43.30473750085367186
Clowse31503750083405593144171206
M,337337500835468
Isenberg34573750083154176114154189210248
D,372237500834556
Merrill379537500835490111133148163178
J,399037500832436
et404337500833456
al.41163750083324760
Dapirolizumab419337500834577116132153190206221250288346379418
pegol462737500833975114152168
demonstrated481237500833873131169208234257279312333367407
significant52353750083264180118133151168200233271292
improvement304738500831572111133170202236294329367389
in344938500831452
systemic35143850083265986109143200216247
lupus37743850083155392130156
erythematosus39433850083345589114152187245277299336363400426
disease43823850083385379114146173208
activity:46033850083316488103135151174207221
efficacy4837385008334527088120153185218
and506838500833270109
safety51903850083265978112135168
results53713850083215582119134304739500832249
of311539500833756
a3190395008332
phase324039500833977110136171
33430395008334
trial3482395008322435991106
[abstract].36073950083184888114138159192224248266278
Arthritis39033950083416287125146162184200226
Rheumatol.414739500833674109147205237259296312324
2024;76(Suppl449039500833468101133145178210229260298337376392
9).49013950083345263
Available498239500834172105120135167206222257
from:52583950083184077136148
https://acrabstracts.org/abstract/dapirolizumab-pegol-demonstrated-significant-improvement-in-systemic-lupus-erythematosus-disease-activity-efficacy-and-safety-results-of-a-54243950083385984304740500833965781041241551872082412803063293513834154394674805185405786046346737007237447778098338608969289679821003104010561071110011381195122812671290133013651405144314581480152115551613165116901716173917601793181518481887191019361951199020282043206020772109214221792201222022362294233323542391242324573047415008357921291501701852232452723043303533864444594905085245616006386646847207417757998378729299619821019104510821108112811681183120912441275130113361359139014221446146114931509153115641586162216401657167517071739177118041826185718951934195619822015203420682090212321442166220022262263227823002327234823872406242624582480
-phase-3-trial/30474250083216199132158193216249271293315330362378403
[cited3466425008318486386119159
2025364042500833469101136
Jul37924250083246277
12].3884425008334648294
44.30474350085367490
Furie31514350083326990105140
RA,33054350083357893
van341143500833265103
Vollenhoven35284350083367288103137176214252284318356
RF,38984350083366975
Kalunian39874350083356884121159174206244
K,424543500833550
et430943500833456
al.43794350083324760
Trial4453435008332506597113
of458043500833756
anti-BDCA246504350083327091107129166212253296332
antibody49964350083327091106145184224256
litifilimab526643500831530526785102117132190222261
for30474450083185678
systemic31404450083265986109142200216247
lupus34034450083155291130156
erythematosus.35744450083345589114152187245278299336363400427440
N4029445008345
Engl408944500833371110125
J4229445008325
Med.426944500835489129142
2022;387:894-904.442644500833569102136149184218251261296330366389424460496509
45.30474550085367186
Merrill314945500835490111133148163178
JT,33444550083245867
Tanaka34274550083336199131161195
Y,363845500833543
D‘Cruz36974550083455999120158187
D,390145500834556
et397345500833456
al.40454550083324760
Efficacy4121455008333516986119151184217
and435445500833270109
safety44794550083265978113135169
of466445500833756
upadacitinib473745500833776109148180212227250265303318357
or511045500833859
elsubrutinib51854550083345076113152174212235250288303342
alone30474650083324785124159
or322246500833859
in329846500831552
combination336746500833168126166181219251273288326365
for37494650083185677
patients38434650083387193108143181203231
with40904650083516689127
systemic42344650083265885108142200215247
lupus44984650083155291130156
erythematosus:46704650083345690115153188246278300337363401427439
a5126465008332
phase517446500833978110136171
25362465008334
randomized54134650083215492304747500833876135150179213252
controlled331547500833168106128149186202217252292
trial.3622475008322435991106119
Arthritis37574750083406286125146161184199225
Rheumatol.399847500833573108146204236258295311324
2024;76:1518-1529.433747500833468101133145178210222252282313344367397427461495506
46.30474850085367489
Morand315148500835493114147185224
E,339048500833346
Pike34514850083354979113
M,357948500835568
Merrill366248500835489110132148163178
JT,38554850083245867
et393748500833456
al.40084850083324760
Deucravacitinib,408348500834580118150171204236269301316339354392407446458
a4556485008332
tyrosine46024850083225678115142156194229
kinase48464850083304684116143178
25038485008335
inhibitor,50874850083155391106145161183220241251
in535348500831553
systemic54204850083265986304749500832256114129162
lupus32294950083155393131158
erythematosus:34074950083345690115154189247280302339366404430443
a3871495008332
phase392349500833978111137173
II,41164950083153143
randomized,41804950083215493132170229244274308348361
double-blind,456249500833876115154170205229269285300339378391
placebo-controlled49734950083395588120154194233257291328367388410448464479514554
trial.3047505008322435991106119
Arthritis31815050083416387125146162185200226
Rheumatol.342250500833674109147205237259296312324
2023;75:242-252.376250500833468101136147180213224259291323344375409443455
47.30475150085366978
Chan313851500834077109146
J,329751500832435
Walters334551500835787102124158178205
GD,35635150083438899
Puri36755150083347192107
P,379451500833540
et384651500833456
al.39145150083324759
Safety39865150083326483117139172
and417051500833269108
efficacy4290515008334527087119151183216
of451851500833756
biological45875150083385391106144183198229261276
agents487651500833170104142163190
in507951500831451
the51435150083215993
treatment52495150083214276107129186221258279
of304752500833757
systemic31195250083265986109142200215247
lupus33825250083155291129156
erythematosus35535250083345589114152187245278299336363400426
(SLE).39955250083185081114134145
BMC415652500833590130
Rheumatol.430252500833574109146204236258295311324
2023;7:37.464152500833569101136148181191226258264
48.30475350085367490
Schett315253500833265103138160184
G,335253500834357
Mackensen342453500835587119149183222248283321
A,376053500834155
Mougiakakos383153500835492131170185217247280311348375
D.422153500834557
CAR429353500834082118
T-cell44275350083325184118133149
therapy45915350083226095116149188219
in482653500831452
autoimmune48935350083327092129145202260298336371
diseases.52795350083385380115146173208235248
Lancet.304754500833165103135169191204
2023;402:2034-2044.326754500833468101136147182218251263298332365401424455489525562575
49.30475550085367285
Schett314655500833265103138160184
G,334455500834457
Müller341555500835492108123157179
F,360755500833339
Taubmann36595550083336199138196228266304
J,397755500832436
et402755500833456
al.40975550083324760
Advancements417155500834179112145183215248306341380401429
and461355500833270109
challenges473655500833169102117132167205244279306
in505555500831553
CAR512255500834082118
T5254555008332
cell5300555008331658196
therapy5409555008322609530475650083215493124
in318656500831553
autoimmune32545650083327092129145202260298336371
diseases.36405650083385379114146173208235248
Nat39045650083447798
Rev401856500833570102
Rheumatol.413656500833573108146204236258295311324
2024;20:531-544.447556500833468101133145180214227262295326345379414451464
50.30475750085367287
Mackensen314757500835486118148182220246281319
A,347857500834155
Müller354657500835492107122156178
F,373657500833338
Mougiakakos378757500835492130169184216246279309346373
D,417257500834556
et424157500833456
al.43105750083314759
Anti-CD19438257500834179100115137180225256286
CAR468157500834082118
T4811575008333
cell4857575008331648094
therapy49645750083226094116148187218
for51955750083185677
refractory5285575008320547395128160184220304758500832155
systemic31175850083265986109143200216248
lupus33805850083155291130156
erythematosus.35515850083345589114152187245278299336363400427440
Nat40075850083447798
Med.412158500835489129142
2022;28:2124-2132.427858500833468101136148183217229265296326358381412443473506518
51.30475950085367082
Hagen314259500834476115150188
M,334459500835468
Bucci342559500833573105136151
L,359059500833145
Böltz36485950083357490112143
S,380459500833345
et386359500833456
al.39325950083324760
BCMA-targeted400559500833677132174195218250272310345367401440
T-cell-engager44595950083325084118133148171207245284316356390412
therapy48845950083226095116149188219
for51175950083185677
autoimmune52085950083316992128144202259297304760500833873
disease.31356050083385379114146173208220
N3370605008345
Engl343060500833370109125
J3570605008324
Med.361060500835489129142
2024;391:867-869.376760500833468101133145180213245254289324357375411447481492
52.30476150085367186
Alexander31476150083415691122155193232266287
T,344761500833342
Krönke35016150083355895133163197
J,371161500832436
Cheng376061500833977112150189
Q,396261500834660
et403561500833456
al.41046150083314759
Teclistamab-induced41766150083336396111126152175208265298337360376414452490522555595
remission478461500832054112127153179194232270
in506761500831552
refractory5132615008321557496129161185221243277
systemic54226150083265885304762500832255113128160
lupus32236250083155291129156
erythematosus.33946250083345589114152187245278299336363400426440
N3849625008345
Engl390962500833371110125
J4049625008325
Med.408962500835489129142
2024;391:864-866.424662500833569102133145180213246254289324361384420455491504
53.30476350085367186
Bucci314963500833573105136151
L,331663500833245
Hagen337763500834477116151189
M,358263500835467
Rothe36656350083367496134169
T,385063500833241
et390763500833456
al.39796350083324860
Bispecific40556350083365177116152184199217234266
T4337635008333
cell4385635008332658196
engager449763500833472111143182217238
therapy47516350083226095116149188220
for49876350083185677
refractory5080635008321557496129161185222244278
rheumatoid53746350083215994132304764500835790111148164203
arthritis.32656450083325378116137152175190216230
Nat35106450083457799
Med.362464500835590129143
2024;30:1593-1601.378264500833468101133145180214227257287319352374405436472503513
54.30476550085367388
Parodis31486550083356788125164179205
I,336665500831528
Girard-Guyonvarc‘h34066550083445980113134172194241279310348386417450471502516554
C,397365500833952
Arnaud403865500834162101133170209
L,426065500833145
et431865500833456
al.43876550083314759
EULAR445965500833376108151186
recommendations46586550083215587124182240275313352384405421458497523
for51946550083185577
the52846550083215994
non-539165500833876114137
-pharmacological30476650083216199132153211243275312328366406421453486501
management356166500835790128160199234292327365386
of396066500833757
systemic40306650083265885108142200215247
lupus42906650083155291129156
erythematosus44596650083345589114152187244277299335362399425
and489766500833270109
systemic50196650083265986109143200216247
sclerosis.52796650083275974109130167194209235248
Ann304767500834179117
Rheum317967500833674109147205
Dis.33996750083456187101
2024;83(6):720-729.351567500833468101133145180214232265283295329363397421452486521532
55.30476850085367185
Saegusa314668500833265100140177204237
K,339768500833549
Tsuchida34606850083335592124162177216248
Y,372268500833544
Komai378068500833472130163178
T,397268500833241
et402768500833456
al.40976850083324760
Advances417168500834179112145183215249276
in446068500831553
targeted45276850083225475114149171205244
therapy47856850083226095116149188219
for50186850083195678
systemic51106850083265885109142200215247
lupus53716850083155392130156
erythematosus:30476950083345589114152187245277299336363400426439
current35016950083316990112146184206
treatments37226950083224377109131189224262284311
and404969500833270109
novel417369500833776108142158
approaches.434669500833271110132169202234272307334348
Int47096950083155374
J4799695008324
Mol483869500835593109
Sci.4962695008333658093
2025;26(3):929.507169500833468101136146181215234267285296332365399410